Skip to main content

Table 3 Age-adjusted HRs and 95% CIs for the association between lifetime recreational physical activity and 15-year all-cause and breast cancer-specific mortality stratified by gene methylation status (methylated vs. unmethylated tumors) among 803 women diagnosed with a first primary breast cancer and with available gene promoter methylation data, Long Island Breast Cancer Study Project

From: Modification of the association between recreational physical activity and survival after breast cancer by promoter methylation in breast cancer-related genes

 

All-cause mortality

Breast cancer-specific mortality

Unmethylated

Methylated

Unmethylated

Methylated

Gene promoter and RPA categories

Deaths/cases–n

HR

95% CI

Deaths/cases–n

HR

95% CI

Deaths/cases–n

HR

95% CI

Deaths/cases–n

HR

95% CI

APC

 Inactive

38/88

1.00

Reference

49/93

1.00

Reference

14/88

1.00

Reference

24/93

1.00

Reference

 <6.36 h/week

54/173

0.83

(0.54–1.26)

38/135

0.46

(0.30–0.70)

21/173

0.64

(0.32–1.27)

16/135

0.35

(0.18–0.65)

 ≥6.36 h/week

40/131

0.71

(0.45–1.10)

46/136

0.60

(0.40–0.80)

16/131

0.63

(0.31–1.29)

26/136

0.58

(0.33–1.02)

p-interaction

0.038

0.138

BRCA1

 Inactive

35/79

1.00

Reference

56/118

1.00

Reference

9/79

1.00

Reference

30/118

1.00

Reference

<6.36 h/week

33/128

0.60

(0.37–0.97)

63/192

0.68

(0.47–0.98)

12/128

0.60

(0.25–1.44)

27/192

0.47

(0.28–0.79)

  ≥ 6.36 h/week

38/119

0.73

(0.46–1.16)

56/167

0.68

(0.47–0.99)

15/119

0.90

(0.40–2.07)

29/167

0.58

(0.35–0.96)

p-interaction

0.485

0.341

CDH1

 Inactive

69/157

1.00

Reference

11/16

1.00

Reference

30/157

1.00

Reference

<5/16

Not estimated

  < 6.36 h/week

88/283

0.73

(0.54–1.01)

<5/15

Not estimateda

35/283

0.54

(0.33–0.89)

<5/15

Not estimated

 ≥6.36 h/week

81/243

0.77

(0.56–1.06)

<5/12

Not estimated

37/243

0.69

(0.43–1.12)

<5/12

Not estimated

p-interaction

Not estimated

Not estimated

CCND2

 Inactive

55/135

1.00

Reference

25/38

1.00

Reference

22/135

1.00

Reference

12/38

1.00

Reference

  < 6.36 h/week

76/244

0.82

(0.58–1.17)

15/54

0.30

(0.16–0.57)

34/244

0.73

(0.43–1.25)

<5/54

not estimated

 ≥6.36 h/week

61/202

0.75

(0.52–1.08)

24/53

0.56

(0.32–0.99)

28/202

0.73

(0.42–1.28)

11/53

0.47

(0.21–1.08)

p-interaction

0.004

Not estimated

DAPK

 Inactive

69/149

1.00

Reference

11/24

1.00

Reference

29/149

1.00

Reference

5/24

1.00

Reference

  < 6.36 h/week

78/259

0.66

(0.47–0.91)

13/39

0.71

(0.32–1.60)

31/259

0.50

(0.30–0.83)

5/39

0.52

(0.15–1.80)

 ≥6.36 h/week

70/216

0.67

(0.48–0.94)

15/39

0.92

(0.42–2.00)

29/216

0.58

(0.34–0.96)

10/39

1.04

(0.36–3.05)

p-interaction

0.467

0.247

ESR1

 Inactive

51/104

1.00

Reference

40/91

1.00

Reference

19/104

1.00

Reference

20/91

1.00

Reference

  < 6.36 h/week

53/178

0.58

(0.39–0.85)

42/138

0.73

(0.47–1.13)

23/178

0.52

(0.28–0.96)

16/138

0.46

(0.24–0.89)

 ≥6.36 h/week

49/155

0.60

(0.41–0.89)

45/129

0.82

(0.54–1.26)

21/155

0.57

(0.30–1.05)

23/129

0.74

(0.40–1.35)

p-interaction

0.298

0.353

GSTP1

 Inactive

47/121

1.00

Reference

33/52

1.00

Reference

19/121

1.00

Reference

15/52

1.00

Reference

  < 6.36 h/week

64/220

0.76

(0.52–1.11)

27/78

0.51

(0.30–0.85)

26/220

0.65

(0.36–1.19)

10/78

0.31

(0.14–0.70)

 ≥6.36 h/week

54/182

0.73

(0.49–1.07)

31/73

0.67

(0.41–1.11)

22/182

0.67

(0.36–1.24)

17/73

0.59

(0.29–1.18)

p-interaction

0.219

0.134

HIN

 Inactive

24/67

1.00

Reference

56/106

1.00

Reference

9/67

1.00

Reference

25/106

1.00

Reference

  < 6.36 h/week

36/113

1.01

(0.60–1.70)

55/185

0.51

(0.35–0.74)

15/113

0.89

(0.39–2.07)

21/185

0.36

(0.20–0.64)

 ≥6.36 h/week

29/88

1.05

(0.61–1.81)

56/167

0.55

(0.38–0.80)

12/88

0.96

(0.40–2.29)

27/167

0.52

(0.30–0.90)

p-interaction

0.016

0.066

P16

 Inactive

76/166

1.00

Reference

9/11

1.00

Reference

31/166

1.00

Reference

7/11

1.00

Reference

  < 6.36 h/week

88/293

0.66

(0.49–0.90)

<5/9

Not estimated

35/293

0.52

(0.32–0.85)

<5/9

Not estimated

 ≥6.36 h/week

82/245

0.71

(0.52–0.98)

<5/10

Not estimated

38/245

0.70

(0.43–1.12)

<5/10

Not estimated

p-interaction

Not estimated

Not estimated

PR

 Inactive

76/174

1.00

Reference

15/23

1.00

Reference

31/174

1.00

Reference

8/23

1.00

Reference

  < 6.36 h/week

87/292

0.66

(0.49–0.91)

9/28

0.75

(0.30–1.90)

32/292

0.50

(0.31–0.82)

7/28

0.67

(0.22–2.10)

 ≥6.36 h/week

80/245

0.71

(0.52–0.97)

14/41

0.79

(0.34–1.80)

36/245

0.71

(0.44–1.15)

8/41

0.55

(0.18–1.64)

p-interaction

0.893

0.226

RARB

 Inactive

52/114

1.00

Reference

28/59

1.00

Reference

18/114

1.00

Reference

16/59

1.00

Reference

  < 6.36 h/week

70/225

0.75

(0.52–1.08)

21/73

0.51

(0.29–0.89)

26/225

0.61

(0.33–1.13)

10/73

0.41

(0.19–0.91)

 ≥6.36 h/week

59/189

0.71

(0.49–1.03)

26/66

0.75

(0.44–1.28)

27/189

0.74

(0.41–1.34)

12/66

0.64

(0.30–1.35)

p-interaction

0.158

0.420

RASSF1A

 Inactive

8/25

1.00

Reference

72/148

1.00

Reference

<5/25

Not estimated

31/148

1.00

Reference

  < 6.36 h/week

10/38

0.73

(0.29–1.88)

81/260

0.65

(0.47–0.90)

5/38

Not estimated

31/260

0.46

(0.28–0.75)

 ≥6.36 h/week

15/47

0.93

(0.39–2.21)

70/208

0.67

(0.48–0.94)

5/47

Not estimated

34/208

0.63

(0.39–1.03)

p-interaction

0.330

Not estimated

TWIST1

 Inactive

60/148

1.00

Reference

20/25

1.00

Reference

25/148

1.00

Reference

9/25

1.00

Reference

  < 6.36 h/week

78/257

0.81

(0.58–1.14)

13/41

0.25

(0.13–0.51)

32/257

0.67

(0.39–1.13)

<5/41

Not estimated

 ≥6.36 h/week

72/214

0.87

(0.61–1.22)

13/41

0.28

(0.14–0.56)

30/214

0.78

(0.46–1.33)

9/41

0.29

(0.11–0.77)

p-interaction

0.001

Not estimated

  1. a Point estimate was not calculated, because cell sizes were less than 5
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us